Experts noted that rapid and extreme weight loss can introduce unique risks, such as a weakened immune system and malnourishment, as well as potentially too much muscle loss. They’re also concerned ...

Eli Lilly wants to take big swings in Alzheimer’s, ALS, chronic pain and other difficult diseases after its success in ...

Eli Lilly Chief Scientific Officer Dan Skovronsky spoke to CNBC about obesity pills and more on the future of weight loss.

The Hong Kong company saw a reduction in body weight across both cohorts with no serious adverse events reported.

Healthcare costs and spending have been rising in the US. The Centers for Medicare & Medicaid Services reported that ...

Ascletis Pharma’s rapid-fire expansion into obesity drug development has passed another milestone. | Ascletis Pharma’s ...

Altimmune's existence depends almost entirely on the outcome of the Phase 2 trial for pemvidutide in MASH. Learn why ALT ...

Pharm Exec’s 20th Annual Pipeline Report examines the emerging drug development trends and surging investments in five ...

Good morning, thank you for joining us for Eli Lilly and Company's Q4 2024 earnings ... we're excited to explore if an oral GLP-1 can also deliver a benefit in this disease. Earlier in the ...

January 2025 kicked off with a wave of impactful biotech deals, setting the stage for an exciting year of innovation.

Eli Lilly has thinned its pipeline ... the active ingredient in Mounjaro and Zepbound, but the GLP-1 candidate emerged as the more promising program. Lilly maintained an interest in the mechanism ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...